Cytoplasmic immunoglobulin content in multiple myeloma.

B Barlogie; R Alexanian; M Pershouse; L Smallwood; L Smith

doi:10.1172/JCI112033

Find articles by Barlogie, B. in: PubMed | Google Scholar

Find articles by Alexanian, R. in: PubMed | Google Scholar

Find articles by Pershouse, M. in: PubMed | Google Scholar

Find articles by Smallwood, L. in: PubMed | Google Scholar

Find articles by Smith, L. in: PubMed | Google Scholar

Published in Volume 76, Issue 2 on August 1, 1985
J Clin Invest. 1985;76(2):765–769. https://doi.org/10.1172/JCI112033.
© 1985 The American Society for Clinical Investigation

Published August 1, 1985 - Version history

Bone marrow cells of 82 patients with multiple myeloma were subjected to flow cytometric analysis of DNA and cytoplasmic immunoglobulin (CIg) content using propidium iodide and direct immunofluorescence assays. Except for two patients with nonsecretory myeloma, there was conformity in the immunoglobulin type derived from immunoelectrophoresis and plasma cell CIg staining. One patient with nonsecretory myeloma exhibited monotypic CIg staining, while the second showed no reaction. In eight patients with IgG lambda myeloma, the same tumor cells contained both lambda and kappa light chains, suggesting the productive rearrangement of both light chain genes. 14 patients with previously unrecognized plasma cells of low RNA content, all of whom were resistant to chemotherapy, were identified by CIg staining. By revealing previously unrecognized plasma cells with low RNA content, CIg analysis identified more patients with treatment-refractory myeloma.

Images.

Click on an image below to see the page. View PDF of the complete article